Drug Approval | December 31, 2022
USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Cipla and Ethris partner for the development of mRNA-based therapies
The new facility will be able to handle four times as many patients as the previous facility.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Surana is a chartered accountant with an all-India rank.
The project will generate and supply green energy to fulfill about 50% present consumption of the company
He has published more than 100 research papers in several prestigious national and international journals
Allam was serving recently as the CEO at Public Investment Fund
Subscribe To Our Newsletter & Stay Updated
